Ind Swift Laboratories logo

Ind Swift Laboratories

INDSWFTLAB NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹3,285 Cr
Volatility
Moderate
P/E Ratio
57.26
EBITDA
₹34.09 Cr
Return on Equity
21.36%
Debt to Equity
0.01
Book Value
₹159.17
52W High
₹404
52W Low
₹87.15

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -6.37% over past five years.
  • Company has a low return on equity of 6.11% over last 3 years.
  • Earnings include an other income of Rs.44.1 Cr.
  • Debtor days have increased from 89.4 to 113 days.
  • Working capital days have increased from 94.1 days to 165 days

Growth Rate

Revenue Growth
-0.28% higher than 3Y
Net Income Growth
-85.66% lower than 3Y
Cash Flow Change
84.39% higher than 3Y
ROE
-52.8% lower than 3Y
ROCE
-68.07% lower than 3Y
EBITDA Margin (Avg.)
-48.65% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
310
290
288
529
33
12
129
138
153
153
151
170
191
Expenses
250
224
236
437
43
24
135
147
149
151
147
149
158
Operating Profit
60
66
52
91
-10
-12
-7
-9
4
1
4
21
33
OPM %
19%
23%
18%
17%
-29%
-99%
-5%
-7%
2.4%
1%
2.8%
12%
17%
Other Income
6
7
7
458
11
13
16
220
15
18
22
-3
7
Interest
20
21
21
3
0
0
10
-27
1
2
1
-2
1
Depreciation
14
13
14
20
0
0
6
7
7
7
9
8
8
PBT
32
39
24
527
1
1
-7
230
10
10
16
12
33
Tax %
45%
18%
19%
6%
-3%
31%
-16%
4%
17%
22%
42%
-26%
25%
Net Profit
17
32
19
494
1
0
-5
222
9
8
10
15
25
EPS in Rs
2.92
5.36
3.29
83.55
0.16
0.07
-0.93
36.67
1.45
0.98
1.17
1.74
2.84
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
660
653
716
765
757
780
891
1,039
1,207
1,281
562
641
665
Expenses
571
546
610
631
630
635
709
837
978
1,029
581
596
605
Operating Profit
89
107
106
134
126
144
183
202
229
252
-19
45
60
OPM %
13%
16%
15%
18%
17%
19%
21%
19%
19%
20%
-3.5%
7%
9%
Other Income
-31
1
15
16
120
33
23
37
7
434
305
36
44
Interest
117
106
88
28
92
107
100
96
92
51
3
1
1
Depreciation
84
85
88
87
104
90
87
131
57
53
24
31
32
PBT
-143
-83
-55
36
50
-20
18
13
87
582
258
49
71
Tax %
-17%
-29%
-29%
39%
42%
7%
117%
117%
45%
28%
3%
16%
—
Net Profit
-119
-59
-39
22
29
-21
-3
-2
48
421
250
41
57
EPS in Rs
-29.14
-14.33
-8.75
4.85
6.09
-3.59
-0.53
-0.36
8.06
71.24
41.32
4.77
6.73
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
42
42
45
46
48
60
60
60
60
59
69
87
Reserves
553
476
486
507
540
581
544
541
622
872
1,104
1,297
Borrowings
1,413
1,457
1,242
1,083
1,148
1,031
1,005
953
862
17
41
18
Other Liabilities
236
240
364
387
188
198
210
247
280
217
224
271
Total Liabilities
2,244
2,215
2,138
2,023
1,924
1,870
1,818
1,801
1,824
1,165
1,438
1,673
Fixed Assets
1,117
1,099
1,042
934
914
843
753
630
587
8
273
306
CWIP
113
78
70
69
20
11
19
10
8
0
0
10
Investments
18
18
18
18
19
17
36
29
30
111
213
248
Other Assets
997
1,020
1,007
1,002
972
998
1,011
1,131
1,199
1,047
952
1,110
Total Assets
2,244
2,215
2,138
2,023
1,924
1,870
1,818
1,801
1,824
1,165
1,438
1,673
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
98
79
96
73
-64
125
135
150
195
-163
-25
-70
Investing
-35
-29
-31
-17
-12
-9
-10
5
-13
-104
-110
-73
Financing
-64
-48
-69
-62
100
-133
-124
-141
-186
699
69
142
Net Cash Flow
-1
3
-4
-6
23
-17
1
14
-4
431
-66
-1
Free Cash Flow
59
49
63
52
-79
114
131
137
182
-205
-51
-156
CFO/OP
111
74
90
54
-51
87
73
74
85
-65
131
-140
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
215
208
182
194
169
186
177
160
153
48
107
113
Inventory Days
312
368
305
291
284
313
301
288
242
6
145
191
Days Payable
120
137
91
118
114
123
111
118
113
52
140
188
Cash Conversion Cycle
407
439
396
367
339
375
367
330
282
2
112
116
Working Capital Days
141
-26
-97
-49
217
248
253
253
234
2
115
165
ROCE %
1%
2%
2%
4%
4%
5%
7%
7%
13%
20%
1%
5%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Ind Swift Laboratories insights

67 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Shareholding Pattern

DIIs0.17%Promot.42.93%FIIs10.70%Others11.75%Public34.45%As ofJun 2026

Documents

1
Concall - Feb 2026 Feb 2026
2
Concall - Jan 2026 Jan 2026
3
Concall - Nov 2020 Nov 2020
4
Concall - Nov 2020 Nov 2020
5
Concall - Jul 2020 Jul 2020

Frequently Asked Questions about Ind Swift Laboratories

What does Ind-Swift Laboratories Ltd do?
Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermato...
Where is Ind-Swift Laboratories Ltd (INDSWFTLAB) listed?
Ind-Swift Laboratories Ltd trades as INDSWFTLAB on the NSE and under code 532305 on the BSE.
Which sector does Ind-Swift Laboratories Ltd belong to?
Ind-Swift Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a market capitalisation of ₹3,285 Cr, which places it in the Small Cap band.
What is the PE ratio of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd trades at a PE ratio of 57.26, against a book value of ₹159.17 per share.
What is the 52-week high and low of Ind-Swift Laboratories Ltd?
Over the last 52 weeks Ind-Swift Laboratories Ltd has traded between ₹87.15 and ₹404.
What is the Return on Equity (ROE) of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd reported a return on equity of 21.36%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermatology. Operations span domestic formulations and international markets through own brands, contract manufacturing and out-licensing.[1]

Website indswiftlabs.com
CEO Mr. Navrattan R. Munjal
Employees 1,246
Listed 1997-07-02
Face Value ₹ 10
Issued Size 8,16,11,558

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDSWFTLAB.md for Ind-Swift Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List